DSIP vs. GHRP-6

Category

Research other

Growth

CAS no.

62568-57-4

87616-84-0

Molecular weight

848.81 g/mol

873.02 g/mol

Half-life

0.1 h

0.4 h

Sequence

DSIP

DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.

GHRP-6

GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.

Highest evidence

Studies

4

4

of which in humans

1

2

Effects recorded

3

4

Open conflicts

1

1

Documented adverse events

1

2